Monthly Archives: February 2012

In recent years, acquisitions of early stage private biotechs have frequently included an upfront value coupled with significant future milestone payments. These earnouts resemble the “biobucks” common to product licensing deals: stretching out over 5-10 years, they get ravaged by

Biogen just announced its acquisition of Stromedix for up to $562M. Another solid M&A exit in biotech emphasizing how innovation matters. With a very different model than Avila Therapeutics, an exit we announced in January, Stromedix is a biology-focused, asset-centric

Biotech pundits often talk about the challenge of raising an initial round of capital for drug discovery startups, highlighting the perceived “gap” in early stage funding.   And it certainly isn’t easy raising that first significant round of institutional capital.  But